Genzyme chief hints at contingency valuation to break Sanofi-Aventis deal impasse
This article was originally published in Scrip
Executive Summary
The stalled, sometimes frosty acquisition bid of the US biotech company Genzyme by France’s Sanofi-Aventis showed signs of thawing today when reading between the lines of an interview of Genzyme’s chief executive officer Henri Termeer in the French daily Le Figaro. During the interview, Mr Termeer discussed so-called poison-pill options available to the Genzyme Board, but also mentioned that the deal could be linked to the success of the performance of Campath, a monoclonal antibody, currently approved for a small indication, a type of B-cell leukaemia, but in late stage clinical development for multiple sclerosis, a much larger market.
You may also be interested in...
AI Firm Healx Raises $56M To Develop Affordable Rare Disease Treatments
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Abalos Raises €12M Series A To Develop Arenavirus-Based Cancer Therapies
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Despite BMS Bid, Celgene Pays $75m Upfront For Immatics Assets Options
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.